What is Zai Lab?
Zai Lab is a specialized bio-pharmaceutical enterprise dedicated to the discovery, development, and commercialization of transformative medicines. Since its inception in 2014, the Shanghai-based firm has focused on addressing significant unmet medical needs, primarily targeting oncology and autoimmune conditions. By leveraging a global R&D model, Zai Lab integrates cutting-edge scientific research with a deep understanding of the regulatory and clinical environments in China and beyond.
The company operates at the intersection of high-science drug discovery and strategic market access. Its business model is characterized by a dual focus: internal innovation and the in-licensing of late-stage assets from global partners. This hybrid strategy allows Zai Lab to maintain a diverse pipeline while mitigating the inherent risks associated with early-stage drug development, positioning it as a critical player in the global healthcare ecosystem.
How much funding has Zai Lab raised?
Zai Lab has raised a total of $1.4B across 6 funding rounds:
Series A
$30M
Series B
$100M
Series C
$30M
Stock Offering
$150M
Share Placement
$261.3M
Stock Offering
$825M
Series A (2014): $30M with participation from TF Capital, Steamboat Ventures, Qiming Venture Partners, and Kleiner Perkins
Series B (2016): $100M led by TF Capital, OrbiMed, Advantech Capital, Qiming Venture Partners, and Steamboat Ventures
Series C (2017): $30M supported by Vivo Capital, OrbiMed, Cormorant Asset Management, and Rock Springs Capital
Stock Issuance/Offering (2017): $150M, investors not publicly disclosed
Share Placement (2020): $261.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $825M, investors not publicly disclosed
Key Investors in Zai Lab
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support companies at various stages of development.
Advantech Capital
Advantech Capital is a private equity fund based in Hong Kong that focuses on innovation-driven growth capital within the TMT, E-services, and healthcare sectors.
Kleiner Perkins
Kleiner Perkins is a prominent venture capital firm that invests in early and growth-stage technology and life science companies, providing both capital and operational support from seed through IPO.
What's next for Zai Lab?
Looking ahead, the recent infusion of capital is expected to accelerate Zai Lab's clinical trial programs and expand its commercial footprint. The company is well-positioned to leverage its current liquidity to advance its late-stage pipeline, potentially bringing several high-impact therapies to market. Strategic priorities likely include the strengthening of its internal R&D capabilities and the pursuit of further global partnerships to enhance its therapeutic portfolio.
As the company transitions into a more mature phase of its lifecycle, the focus will shift toward operational efficiency and the successful commercialization of its lead assets. Investors will be closely monitoring the firm's ability to navigate the evolving regulatory landscape and maintain its competitive edge in the high-stakes biopharmaceutical industry. The sustained backing from top-tier institutional investors provides a stable foundation for Zai Lab to continue its mission of delivering innovative healthcare solutions to patients worldwide.
